Key result
Pomegranate pretreatment significantly attenuated daunorubicin-induced cardiac damage, reducing serum cardiac troponin I levels from 211.20 pg/ml to 82.815 pg/ml.
Why the study?
Does pomegranate pretreatment reduce daunorubicin-induced cardiotoxicity in Sprague male rats?
Does pomegranate pretreatment reduce daunorubicin-induced cardiotoxicity in Sprague male rats?
Pomegranate pretreatment demonstrates potential cardioprotective effects against daunorubicin-induced cardiotoxicity in a rat model by reducing oxidative stress and inflammation.
Answers are grounded in this paper and cite their sources.
Pomegranate may attenuate daunorubicin cardiotoxicity in rats; hypothesis-generating and should not change practice.
BACKGROUND: Daunorubicin-induced acute cardiotoxicity caused by oxidative stress and free radical formation. Pomegranate possessed a significant in vitro free radical scavenging activity. Therefore, the aim of this study was estimations of the role of pomegranate effects in daunorubicin-induced cardiotoxicity. METHODS: A total of 21 Sprague male rats were allocated into three groups, seven animals in each group. Group A: Control group received distilled water. Group B: Treated group with daunorubicin 20 mg/kg via intraperitoneal injection daily for the 12(th) day for total cumulative dose of 240 mg/kg. Group C: Pretreatment group with pomegranate 25 mg/kg for 6 days orally, then daunorubicin 20 mg/kg administrated concomitantly for the next 6 days with a cumulative dose of 120 mg/kg. Cardiac troponin I([cTn I] pg/ml), malondialdehyde (MDA) (ng/ml), interleukin 17 (IL-17 pg/ml), and cardiac lactate dehydrogenase (LDH) (pm/ml), all these biomarkers were used to measure the severity of cardiotoxicity. RESULTS: Daunorubicin at a dose of 20 mg/kg lead to pronounced cardiac damage that reflected on through elevations of serum cTn and serum LDH levels significantly P < 0.01, it induced lipid peroxidation during cardiotoxicity that reflected through an elevation in the serum MDA significantly P < 0.01, moreover, daunorubicin induces pro-inflammatory changes in cardiotoxicity; it raises the IL-17 serum level significantly P < 0.01 as compared with control. Pomegranate pretreatment demonstrated a significant cardioprotection from daunorubicin-induced cardiotoxicity; it attenuated the cardiac damage through reduction of cTn, LDH, MDA, and serum IL-17 level significantly P < 0.01 as compared with daunorubicin-treated group. CONCLUSIONS: Pomegranate demonstrated significant cardioprotection in daunorubicin-induced cardiotoxicity through reduction of oxidative stress, lipid peroxidation, pro-inflammatory, and cardiac injury biomarkers.
No takes yet. Share an insight, caveat, or question.
Al‐kuraishy et al. (2016) studied Daunorubicin-induced cardiotoxicity (n=21). Pomegranate vs. Daunorubicin 20 mg/kg alone was evaluated on Serum cardiac troponin I (cTn I) (95% CI -123.02-133.74, p=0.00012). Pomegranate pretreatment significantly attenuated daunorubicin-induced cardiac damage, reducing serum cardiac troponin I levels from 211.20 pg/ml to 82.815 pg/ml.
Synapse has enriched 10 related papers. Consider them for comparative context: